Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT00951665 (Clinical Trial/ Ado-Trastuzumab Emtansine)

Study Title
A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer (NCT00951665)

Trial Description
This Phase Ib-IIa, multi-institutional, open-label, dose-escalation study is designed to evaluate the safety, tolerability, pharmacokinetics and feasibility of ado-trastuzumab emtansine (T-DM1, Kadcyla®; Genentech, Inc.) administered by intravenous (IV) infusion in combination with paclitaxel (Abraxane®; Celgene Corp.) and pertuzumab (Perjeta®; Genentech, Inc.), if applicable, in patients with HER2-positive, locally advanced or metastatic breast cancer.

This trial is sponsored by Genentech, Inc. [1]

Study Data

  • Condition: Metastatic Breast Cancer
  • Interventions:
  • Phase: I
  • Enrollment: 107
  • Start: August 2009
  • Completion: June 2013
  • Last verified: July 2015

Study Schematic

(Coming soon)

Click here to Return to Drug map


Last Editorial review: July 30, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar